People with advanced forms of cancer have exhibited favorable clinical response to the long-term use of synthetic cannabidiol (CBD), according to data published in the journal Anticancer Research.
Over 90% of patients in the study exhibited a clinical response to CBD treatment, with some patients experiencing a reduction in tumor cell proliferation and tumor size, NORML reported.
The British researchers assessed the effects of twice-daily, synthetic CBD administration on 119 cancer patients over a four-year period. Patients consumed the oil for a minimum of six months.
“The fact that we have been able to document improvement … strongly supports further studies of CBD-based products in cancer patients who have exhausted standard treatments,” the researchers concluded.
Prior studies have demonstrated cannabinoids, particularly CBD and THC, to possess anti-cancer properties in pre-clinical models. However, to date, this has not been replicated in a controlled human trial.